What Goes Down Just Went Up: Aβ Climbs in Mouse CSF Before Dropping
The signature fall of cerebrospinal fluid concentrations of Aβ that herald Alzheimer’s may be preceded by a brief boost.
589 RESULTS
Sort By:
The signature fall of cerebrospinal fluid concentrations of Aβ that herald Alzheimer’s may be preceded by a brief boost.
Two large studies measured the occurrence of amyloid pathology in people with AD and other dementias. They confirm that amyloid may precede dementia onset by more than two decades, and rises with age, particularly in people with the ApoE4 gene.
Scientists find neurodegenerative proteins squirreled away in the skin cells of patients. Could this present an untapped source of biomarkers?
Several different striatal markers may help researchers track early deterioration in Huntington's and Parkinson’s diseases.
People with at least 16 years of education are less likely to accumulate markers of neurodegeneration in their brains, says a cross-sectional study.
Deep brain stimulation helps many people with Parkinson’s, but how it does so remains a mystery. A new study suggests it normalizes brain rhythms.
The highs and lows of cerebrospinal fluid Aβ and PET amyloid imaging don't necessarily agree.
Qualification could follow, but only if trial sponsors fork over fresh data.
Two new open-access journals will cover specialized areas of Alzheimer’s research.
Cognitively normal people with levels of CSF Aβ42 near the cutoff point associated with amyloid pathology are likely to cross that threshold within three years.
Early data suggest that the T807/AV1451 signal relates to cerebrospinal biomarkers of Alzheimer’s, intensifies by up to 10 percent a year, and might nail diagnoses beyond typical AD.
For the first time, scientists report a crystal structure of TSPO, a potential target for PET imaging of neuroinflammation.
Spinal taps have a bad rap. Are headaches really all that common afterwards, and are there ways to prevent them?
Imaging technique borrowed from cancer care shows that leaks are worse in people who are cognitively impaired.
All three PET agents demonstrate roughly equivalent abilities to detect brain amyloid, a new analysis finds.